Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00913510
Recruitment Status : Terminated
First Posted : June 4, 2009
Results First Posted : January 6, 2014
Last Update Posted : January 6, 2014
Sponsor:
Information provided by (Responsible Party):
Wellspect HealthCare

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The aims of this prospective, randomized study are:

  • To assess the effect of clean intermittent catheterization (CIC)
  • To investigate if MS patients will have symptom reduction (urgency, frequency, nocturia and incontinence) when using CIC in combination with anticholinergic drugs
  • To identify at what volume of Postvoid Residual (PVR) urine, starting CIC improves bladder control and QoL
  • To increase the evidence of CIC, and support clinical guidelines of bladder management in MS patients

Condition or disease Intervention/treatment Phase
Bladder Dysfunction Multiple Sclerosis Device: CIC using LoFric Primo Drug: Anticholinergic medication Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy of Clean Intermittent Self-catheterization in Combination With Anticholinergic Drugs for Treatment of Bladder Dysfunction in Multiple Sclerosis
Study Start Date : December 2009
Actual Primary Completion Date : May 2012

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: CIC using LoFric Primo
Anticholinergic medication according to clinical practice and investigator´s judgement and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
 Device: CIC using LoFric Primo
Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
Other Name: LoFric Primo

Drug: Anticholinergic medication
Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
Active Comparator: Anticholinergic medication
Anticholinergic medication according to clinical practice and investigator´s judgement, i.e. Drug.
 Drug: Anticholinergic medication
Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percent Change From Baseline in Frequency of Micturition Per Day at 8 Weeks. [ Time Frame: Baseline and 8 weeks after randomization. ]
    Number of micturitions per day was assessed using a patient diary during three days at baseline and after 8 weeks of treatment. The relative change in mean number of micturitions was compared between the groups. The change was calculated as percent change = ((measure at 8 weeks - measure at baseline)/measure at baseline)*100%.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of informed consent
  • Male and female patients aged 18 years and over
  • MS patients that are already currently treated or eligible for treatment with anticholinergic drugs
  • Patient with previously confirmed multiple sclerosis according to McDonald Criteria and level of disability less than 6.5 on the Kutzke scale and have been stable for 6 months
  • The patient has all or any bladder symptoms; urgency, frequency, incontinence, nocturia, PVR
  • The patient has Frequency symptoms > 8 voiding per 24 h
  • The patient has PVR > 50 ml, measured at two repetitive bladder scan measurements during the screening phase as well as the randomization visit
  • Adequate mobility to lower limbs, sufficient hand function and ability to practice CIC at least three times daily

Exclusion Criteria:

  • Pregnancy
  • Ongoing symptomatic Urinary Tract Infection (UTI) as judged by investigator
  • Involvement in the planning and conduct of the study (applies to both Astra Tech staff or staff at the study site)
  • The patient practices CIC prior the study
  • The patient has undergone a sphincterectomy
  • Progressive "Relapsing- remitting MS" as judged by the investigator
  • Severe non-compliance to protocol as judged by the investigator and/or Astra Tech
  • The patient is participating in other study that might have an impact on the outcome of this, as judged by investigator
  • PVR > 250 ml, measured at two repetitive bladder scan measurements during the screening phase as well as the randomization visit and or if Bladder Voiding Efficiency (BVE) at visit 2 (randomization) is 50% or less than visit 1 (screening)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00913510


Locations
Layout table for location information
Belgium
Centre Hospitalier Universitaire de Liège Ourthe Ambléve
Esneux, Belgium, 4130
UZ Gasthuisberg
Leuven, Belgium, 3000
Germany
St. Hedwig Hospital, Department of Urology
Berlin, Germany, 10115
Netherlands
UMC ST Radboud Nijmegen, Department of Urology
Nijmegen, Netherlands, 6500 HB
United Kingdom
University College of London, Institute of Neurology
London, United Kingdom, WC1N 3BG
Sponsors and Collaborators
Wellspect HealthCare
Investigators
Layout table for investigator information
Principal Investigator: Clare Fowler, Prof. University College, London
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Wellspect HealthCare
ClinicalTrials.gov Identifier: NCT00913510    
Other Study ID Numbers: YA-MSP-0001
First Posted: June 4, 2009    Key Record Dates
Results First Posted: January 6, 2014
Last Update Posted: January 6, 2014
Last Verified: January 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
 Autoimmune Diseases
Immune System Diseases
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs